Loading...
Loading...
ACER| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,263.1K |
| Operating I/L | -5,263.1K |
| Other Income/Expense | -4,121.2K |
| Interest Income | 0.0K |
| Pretax | -9,384.3K |
| Income Tax Expense | 1,855.2K |
| Net Income/Loss | -11,239.5K |
Acer Therapeutics Inc. is a pharmaceutical company specializing in the acquisition, development, and commercialization of therapies for rare and life-threatening diseases. The company's pipeline includes EDSIVO for vascular Ehlers-Danlos Syndrome, ACER-001 for inborn errors of metabolism, ACER-801 for Vasomotor Symptoms, and ACER-2820 for infectious diseases, including COVID-19. Acer generates revenue through the development and commercialization of these clinical-stage candidates, as well as through research collaborations and license agreements with organizations such as the National Center for Advancing Translational Sciences and Sanofi.
